Stock Price Quote

MEDICAMEN BIOTECH LTD.

NSE : MEDICAMEQBSE : 531146ISIN CODE : INE646B01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE305.35-3.25 (-1.05 %)
PREV CLOSE ( ) 308.60
OPEN PRICE ( ) 296.25
BID PRICE (QTY) 300.70 (8)
OFFER PRICE (QTY) 305.45 (10)
VOLUME 1371
TODAY'S LOW / HIGH ( )296.25 307.75
52 WK LOW / HIGH ( )210.1 454
NSE300.85-3.85 (-1.26 %)
PREV CLOSE( ) 304.70
OPEN PRICE ( ) 304.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 11443
TODAY'S LOW / HIGH( ) 298.00 305.00
52 WK LOW / HIGH ( )212.4 447.65
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1993
Management Info
Rahul Bishnoi - Chairman - Managing Director
Registered Office

Address 1506,Chiranjiv Tower,43, Nehru Place,
New Delhi,
Delhi-110019

Phone 011-47589500-51

Email info@medicamen.com

Website www.medicamen.com

Registrars Details
MUFG Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
 Listing : BSE, NSE

NEWS

20May Medicamen Biotech informs about board
Pursuant to Regulation 29 read with Regulation 33 and other applicable p..
03Jun Medicamen Biotech gets USFDA’s approva
Medicamen Biotech has received its first Abbreviated New Drug Applicatio..
03Apr Medicamen Biotech signs contract for C
Medicamen Biotech has signed a contract for CDMO with XGX pharma, Europe..
31Mar Medicamen Biotech informs about closur
In terms of the provisions of the Code of Conduct to Regulate, Monitor a..
22Mar Medicamen Biotech informs about disclo
Medicamen Biotech has informed that it enclosed disclosure dated March 2..
MORE

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit25.2794.0800000000001
Gross Profit 32.58 115.47
Operating Profit 56.41213.9
Net Sales 438.531788.46
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  25999.85 (1.44%)
M.Cap ( in Cr)55247.87
Astrazeneca Pharma (BSE)
peergroup  5831.85 (2.24%)
M.Cap ( in Cr)14579.63
Acutaas Chemicals (BSE)
peergroup  3160.05 (3.33%)
M.Cap ( in Cr)25871.68
Glenmark Pharma. (BSE)
peergroup  2291.25 (3.69%)
M.Cap ( in Cr)64664.73
Pfizer (BSE)
peergroup  3811.25 (1.65%)
M.Cap ( in Cr)17435.60
MORE

Shareholding Pattern

NON-INSTITUTION 59.02%
PROMOTERS 40.46%
GOVERNMENT 0.05%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
FII 0%
MORE

About Medicamen Biotech Ltd.

Medicamen Biotech Ltd. was incorporated in the year 1993. Its today's share price is 305.35. Its current market capitalisation stands at Rs 414.14 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1514.63 Cr and Total Income of Rs.1576.94 Cr. The company's management includes Shaival Saurabh, Parul Choudhary, Sham Goel, Sumita Dwivedi, Ravi Kumar Bansal, Sanjay Bansal, Suresh Kumar Singh, Ashwani Kumar Sharma, Vimal Kumar Shrawat, Rahul Bishnoi.

It is listed on the BSE with a BSE Code of 531146 , NSE with an NSE Symbol of MEDICAMEQ and ISIN of INE646B01010. It's Registered office is at 1506,Chiranjiv Tower,43, Nehru PlaceNew Delhi-110019, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Ashok Sharma & Associates, Rai Qimat & Associates

download beyond app
download beyond app

About Nirmal Bang

About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support

Product & Services

Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Algo Trading

Equity

Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities

Derivatives

Updates Market Report Overview

IPO

IPO Issues Performance News & Analysis

Commodities

Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges

Portfolio Management Service (PMS)

PMS Disclosure Document Nirmal Bang PMS - Investor Charter NB PMS Insights SCORES complaints – August 2026 Online Grievance Portal – SCORES Online Dispute Resolution Portal – ODR Fee Calculator UPI ID - QR Code & Forms Empaneled Distributors Contact Us

Mutual Funds

About Nirmal Bang Wealth Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy

NPS

NPS Forms and Guidelines NPS-AML Policy NPS - Operational Guidelines

Nirmal Bang Research

Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data Important Update IRRA

Other Links

Disclaimer Privacy Policy Policies and Procedures Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SCORES and ‘SMARTODR portal
RMS Policy
RMS Policy Auto Square Off Policy
Inspection SORM Policy - NBEPL CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023 FY-2023-2024 FY-2024-2025 FY-2025-2026 FY-2026-2027
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker RA NBEPL Investor Charter RA NBSPL Investor Charter Investor Complaints -RA Investor Complaints-NBEPL Investor NBCPL Investor NBEPL RA Investor NBSPL-RA
Evoting
NSDL Evoting CDSL Evoting
Compliance Annual report
NBSPL ACR Report Signed Annexure – NBSPL NBEPL ACR Report Signed Annexure – NBEPL
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’s Surrendered List of AP’s KYC Activation Process Voluntary Freezing Blocking of Online Trading Account Internal Shortage Policy MCXCCL Client Reports Policy For GTC/GTD RBI Guidelines Transfer of Funds via SEBI-Validated UPI ID MTF Terms Master Circular for Online Dispute Resolution
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatment NBSPL Policy of AML NBEPL Policy of AML NBSPL Policy of Surveillance NBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For Any Legal Department Grievances – Level 1, Please Get In Touch With Mr. Bhavin Pandya On 022-6273 9232 Or Write A Mail To bhavin.pandya@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Legal Department Grievances – Level 2, Please Get In Touch With Mr. Kishor Kumar Agrawal On 022-6273 9252/9253 Or Write A Mail To kishorkumar.agrawal@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Compliance Grievances / other grievances , Please Get In Touch With Mr. Samir Kamdar On 022-62739395/9396 Or Write A Mail To samir.kamdar@nirmalbang.com With Subject line As Grievances/Complaint.     |    
IMPORTANT LINKS: SEBI BSE NSE MCX CDSL NSDL NCDEX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.